Chris Bernard Threatt, MD
Urology · Redwood City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 4 carriers
- Offices
- 2
Offices
2 locations · UCSF Health Medical Foundation · El Camino Health Medical Network LLC
Hospitals listed: El Camino Health · Mills-Peninsula Medical Center · Sequoia Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Threatt’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A79072 · Current
Licensed to practise in California · since 2002 · expires 2027-07-31 · University of California, Irvine College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$288,741
Medicare paid this office $288,741 for 531 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 472 | $120,506 | $103 |
| Diagnostic exam of bladder and urethra using an endoscope | 103 | $28,740 | $214 |
| Insertion of lower leg neurostimulator electrode | 16 | $11,347 | $100 |
| New patient visit (45+ min) | 86 | $11,184 | $130 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 15 | $8,526 | $533 |
See all 16 services
| Return visit (30+ min) | 472 | $120,506 | $103 |
| Diagnostic exam of bladder and urethra using an endoscope | 103 | $28,740 | $214 |
| Insertion of lower leg neurostimulator electrode | 16 | $11,347 | $100 |
| New patient visit (45+ min) | 86 | $11,184 | $130 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 15 | $8,526 | $533 |
| Short return visit (20+ min) | 70 | $6,982 | $76 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 13 | $4,253 | $327 |
| Injection of drug or substance under skin or into muscle | 104 | $3,198 | $12 |
| Ultrasound measurement of bladder capacity after voiding | 200 | $2,663 | $9 |
| Electronic assessment of bladder emptying | 194 | $2,533 | $10 |
| Simple bladder irrigation and/or instillation | 23 | $2,138 | $59 |
| Long return visit (40+ min) | 14 | $1,867 | $133 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 36 | $1,446 | $21 |
| Injection, garamycin, gentamicin, up to 80 mg | 83 | $424 | None |
| Urinalysis, manual test | 14 | $92 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 13 | $25 | None |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
| Removal of skin lesions | 1-10 | None |
Who their Medicare patients are
531 Original Medicare patients in 2024. Average age 78 · Women 20% · Also on Medicaid 3% · Health risk score 1.17. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Coronary heart disease 36% · Cancer 27% · Atrial fibrillation 25% · Diabetes 24% · Chronic kidney disease 23% · Heart failure 15% · COPD 10% · Depression 10% · Dementia 6% · Stroke 6%.
The office billed $1,391,524, Medicare allowed $390,484 and paid $288,741; for 11,210 services of 89 kinds; $21,297 of it was for drugs given in the office and $267,444 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 531 | 11,210 | 78 | 1.17 | $1,391,524 | $288,741 |
| 2023 | 463 | 6,581 | 78 | 1.06 | $1,151,989 | $267,104 |
| 2022 | 427 | 4,593 | 77 | 1.00 | $889,624 | $226,608 |
| 2021 | 464 | 4,852 | 77 | 1.02 | $897,496 | $235,672 |
| 2020 | 541 | 6,305 | 77 | 1.14 | $1,082,057 | $238,819 |
| 2019 | 772 | 6,773 | 77 | 1.15 | $932,807 | $361,421 |
| 2018 | 771 | 8,600 | 77 | 1.17 | $1,303,192 | $477,674 |
| 2017 | 850 | 9,761 | 77 | 1.19 | $1,342,748 | $464,764 |
| 2016 | 833 | 6,406 | 77 | 1.16 | $1,179,700 | $438,470 |
| 2015 | 820 | 5,440 | 77 | 1.19 | $1,003,808 | $374,347 |
| 2014 | 810 | 5,648 | 77 | 1.14 | $1,090,692 | $375,220 |
| 2013 | 787 | 6,774 | 78 | 1.14 | $1,142,792 | $408,311 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Return visit (30+ min) | 403 | $101,632 | $111 |
| Diagnostic exam of bladder and urethra using an endoscope | 73 | $23,724 | $235 |
| Insertion of lower leg neurostimulator electrode | 24 | $23,354 | $117 |
| New patient visit (45+ min) | 62 | $8,865 | $143 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 12 | $6,979 | $582 |
| Long return visit (40+ min) | 33 | $6,688 | $167 |
| Dilation of urethra using an endoscope | 13 | $5,548 | $326 |
| Short return visit (20+ min) | 55 | $4,766 | $79 |
| Ultrasound measurement of bladder capacity after voiding | 234 | $3,771 | $10 |
| Injection of drug or substance under skin or into muscle | 92 | $3,153 | $13 |
| New patient visit (60+ min) | 14 | $2,846 | $203 |
| Electronic assessment of bladder emptying | 172 | $2,706 | $11 |
| Simple bladder irrigation and/or instillation | 22 | $1,973 | $64 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 32 | $1,295 | $22 |
| Injection, garamycin, gentamicin, up to 80 mg | 73 | $412 | None |
| Urinalysis, manual test | 22 | $92 | $3 |
2022: 13 services
| Return visit (30+ min) | 359 | $84,049 | $112 |
| Diagnostic exam of bladder and urethra using an endoscope | 54 | $18,209 | $233 |
| Insertion of lower leg neurostimulator electrode | 12 | $12,431 | $121 |
| Short return visit (20+ min) | 86 | $9,085 | $82 |
| Long return visit (40+ min) | 39 | $8,650 | $166 |
| New patient visit (45+ min) | 36 | $5,143 | $143 |
| Ultrasound measurement of bladder capacity after voiding | 228 | $3,404 | $10 |
| Electronic assessment of bladder emptying | 183 | $2,704 | $11 |
| Injection of drug or substance under skin or into muscle | 78 | $2,600 | $13 |
| Simple bladder irrigation and/or instillation | 26 | $1,886 | $61 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 40 | $1,065 | $18 |
| Urinalysis, manual test | 88 | $543 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 62 | $272 | None |
2021: 15 services
| Return visit (30+ min) | 353 | $77,249 | $116 |
| Insertion of lower leg neurostimulator electrode | 22 | $26,931 | $131 |
| Diagnostic exam of bladder and urethra using an endoscope | 81 | $23,437 | $223 |
| Short return visit (20+ min) | 154 | $19,482 | $80 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 11 | $6,761 | $615 |
| New patient visit (45+ min) | 34 | $5,084 | $150 |
| Ultrasound measurement of bladder capacity after voiding | 223 | $3,393 | $10 |
| Injection of drug or substance under skin or into muscle | 109 | $3,364 | $13 |
| Long return visit (40+ min) | 17 | $2,918 | $172 |
| Electronic assessment of bladder emptying | 167 | $2,530 | $11 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 61 | $2,343 | $21 |
| Simple bladder irrigation and/or instillation | 23 | $1,971 | $66 |
| Urinalysis, manual test | 86 | $619 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 93 | $375 | None |
| Injection, ceftriaxone sodium, per 250 mg | 20 | $53 | None |
2020: 17 services
| Return visit (30+ min) | 438 | $75,565 | $90 |
| Insertion of lower leg neurostimulator electrode | 25 | $19,481 | $128 |
| Diagnostic exam of bladder and urethra using an endoscope | 63 | $16,064 | $209 |
| Short return visit (20+ min) | 152 | $11,732 | $58 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $10,033 | None |
| New patient visit (45+ min) | 58 | $7,223 | $125 |
| Dilation of urethra using an endoscope | 14 | $5,205 | $306 |
| Ultrasound measurement of bladder capacity after voiding | 207 | $2,820 | $10 |
| Injection of drug or substance under skin or into muscle | 98 | $2,547 | $14 |
| Electronic assessment of bladder emptying | 146 | $2,238 | $12 |
| Simple bladder irrigation and/or instillation | 24 | $1,705 | $59 |
| Long return visit (40+ min) | 14 | $1,617 | $116 |
| New patient visit (30+ min) | 17 | $1,248 | $73 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 21 | $795 | $23 |
| Urinalysis, manual test | 56 | $337 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 82 | $267 | None |
| Simple timed assessment of bladder emptying | 32 | $222 | $6 |
2019: 25 services
| Return visit (30+ min) | 499 | $83,359 | $92 |
| Short return visit (20+ min) | 337 | $31,031 | $63 |
| Insertion of lower leg neurostimulator electrode | 26 | $30,267 | $126 |
| Diagnostic exam of bladder and urethra using an endoscope | 107 | $25,116 | $181 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $11,857 | None |
| Botox | 14 | $11,530 | None |
| New patient visit (45+ min) | 80 | $10,843 | $136 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 17 | $10,604 | $624 |
| Dilation of urethra using an endoscope | 31 | $9,498 | $288 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 14 | $6,262 | $330 |
| Long return visit (40+ min) | 35 | $5,010 | $122 |
| New patient visit (30+ min) | 54 | $4,564 | $85 |
| Ultrasound measurement of bladder capacity after voiding | 268 | $4,474 | $12 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 12 | $4,150 | $346 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $2,636 | $240 |
| Simple bladder irrigation and/or instillation | 37 | $2,614 | $51 |
| Electronic assessment of bladder emptying | 156 | $2,207 | $12 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,811 | $107 |
| Injection of drug or substance under skin or into muscle | 37 | $1,474 | $14 |
| Simple insertion of temporary bladder tube | 11 | $1,161 | $61 |
| Urinalysis, manual test | 121 | $699 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 117 | $419 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $359 | $22 |
| Imaging of urinary tract following injection of a contrast agent | 15 | $328 | $22 |
| Injection, ceftriaxone sodium, per 250 mg | 20 | $62 | None |
2018: 32 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 17 | $66,725 | $953 |
| Return visit (30+ min) | 410 | $66,043 | $89 |
| Insertion of lower leg neurostimulator electrode | 49 | $53,734 | $120 |
| Short return visit (20+ min) | 469 | $43,169 | $56 |
| Diagnostic exam of bladder and urethra using an endoscope | 140 | $26,893 | $148 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 17 | $20,689 | $1,217 |
| Botox | 16 | $14,838 | None |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 20 | $12,229 | $582 |
| Complete ultrasound scan behind abdominal cavity | 92 | $11,524 | $52 |
| Complete ultrasound scan of pelvis | 92 | $11,143 | $52 |
| New patient visit (45+ min) | 73 | $9,508 | $130 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 30 | $9,352 | $302 |
| Ultrasound measurement of bladder capacity after voiding | 315 | $7,243 | $14 |
| Dilation of urethra using an endoscope | 20 | $6,453 | $248 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 16 | $6,293 | $286 |
| New patient visit (30+ min) | 71 | $6,032 | $85 |
| Electronic assessment of bladder emptying | 260 | $4,663 | $12 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,688 | $335 |
| Long return visit (40+ min) | 28 | $3,678 | $119 |
| Insertion of device into abdomen with pressure and urine flow rate study | 30 | $3,319 | $107 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 13 | $3,098 | $221 |
| Simple insertion of temporary bladder tube | 15 | $2,548 | $54 |
| Simple bladder irrigation and/or instillation | 43 | $2,513 | $44 |
| Injection of drug or substance under skin or into muscle | 32 | $2,202 | $17 |
| New patient visit (60+ min) | 11 | $1,808 | $164 |
| Urinalysis, manual test | 163 | $1,009 | $3 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 30 | $977 | $32 |
| Injection procedure to cause erection | 11 | $897 | $82 |
| Injection, garamycin, gentamicin, up to 80 mg | 175 | $551 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $180 | $16 |
| Imaging of urinary tract following injection of a contrast agent | 12 | $180 | $15 |
| Injection, ketorolac tromethamine, per 15 mg | 12 | $10 | None |
2017: 39 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 21 | $76,997 | $939 |
| Short return visit (20+ min) | 582 | $66,052 | $58 |
| Return visit (30+ min) | 338 | $50,280 | $83 |
| Diagnostic exam of bladder and urethra using an endoscope | 145 | $27,191 | $146 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 22 | $26,424 | $1,201 |
| Botox | 20 | $17,316 | None |
| Insertion of lower leg neurostimulator electrode | 21 | $16,210 | $119 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 23 | $13,403 | $583 |
| Ultrasound measurement of bladder capacity after voiding | 376 | $11,483 | $18 |
| New patient visit (45+ min) | 76 | $9,659 | $127 |
| Complete ultrasound scan behind abdominal cavity | 70 | $8,374 | $47 |
| Complete ultrasound scan of pelvis | 69 | $8,373 | $48 |
| New patient visit (30+ min) | 98 | $7,964 | $81 |
| Dilation of urethra using an endoscope | 25 | $7,887 | $246 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 20 | $7,192 | $277 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 24 | $6,810 | $272 |
| Electronic assessment of bladder emptying | 232 | $4,361 | $12 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,612 | $328 |
| Injection of drug or substance under skin or into muscle | 41 | $3,576 | $22 |
| Long return visit (40+ min) | 21 | $3,149 | $121 |
| Simple insertion of temporary bladder tube | 22 | $3,088 | $55 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 12 | $2,833 | $218 |
| Insertion of device into abdomen with pressure and urine flow rate study | 24 | $2,626 | $105 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,530 | $101 |
| Urinalysis, manual test | 355 | $2,261 | $3 |
| Simple bladder irrigation and/or instillation | 46 | $2,058 | $37 |
| Ultrasound scan of pelvic region through rectum | 19 | $1,707 | $90 |
| Short return visit (20+ min) | 30 | $1,564 | $36 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,080 | $60 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 28 | $939 | $32 |
| Diagnostic exam of bladder and urethra using an endoscope | 11 | $784 | $71 |
| Insertion of stent in ureter using an endoscope | 11 | $716 | $60 |
| Injection, garamycin, gentamicin, up to 80 mg | 202 | $627 | None |
| Short return visit | 16 | $625 | $39 |
| New patient visit (30+ min) | 13 | $614 | $47 |
| Imaging of urinary tract following injection of a contrast agent | 24 | $387 | $15 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $298 | $17 |
| Injection, ceftriaxone sodium, per 250 mg | 15 | $35 | None |
| Injection, ketorolac tromethamine, per 15 mg | 19 | $24 | None |
2016: 34 services
| Return visit (30+ min) | 435 | $66,832 | $90 |
| Short return visit (20+ min) | 509 | $53,747 | $61 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 12 | $39,999 | $1,000 |
| Diagnostic exam of bladder and urethra using an endoscope | 133 | $34,983 | $190 |
| Insertion of lower leg neurostimulator electrode | 26 | $26,325 | $127 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $15,660 | None |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 12 | $15,307 | $1,276 |
| New patient visit (45+ min) | 105 | $14,815 | $141 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 22 | $13,199 | $600 |
| Ultrasound measurement of bladder capacity after voiding | 422 | $12,970 | $18 |
| Complete ultrasound scan behind abdominal cavity | 61 | $7,798 | $51 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 23 | $7,514 | $313 |
| Complete ultrasound scan of pelvis | 58 | $6,091 | $42 |
| Electronic assessment of bladder emptying | 263 | $5,180 | $13 |
| New patient visit (30+ min) | 61 | $5,070 | $83 |
| Dilation of urethra using an endoscope | 13 | $4,177 | $261 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,980 | $362 |
| Ultrasound scan of pelvic region through rectum | 33 | $3,103 | $91 |
| Injection of drug or substance under skin or into muscle | 30 | $3,045 | $21 |
| Simple insertion of temporary bladder tube | 22 | $2,947 | $64 |
| Urinalysis, manual test | 456 | $2,810 | $3 |
| Insertion of device into abdomen with pressure and urine flow rate study | 23 | $2,664 | $111 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $2,527 | $230 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 24 | $2,363 | $95 |
| Biopsy of prostate gland | 11 | $2,226 | $186 |
| Short return visit (20+ min) | 28 | $1,861 | $36 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,549 | $119 |
| Return visit (30+ min) | 12 | $932 | $58 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $775 | $32 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $392 | $19 |
| Imaging of urinary tract following injection of a contrast agent | 18 | $314 | $16 |
| Injection, garamycin, gentamicin, up to 80 mg | 159 | $247 | None |
| Injection, cefotaxime sodium, per gm | 15 | $75 | None |
| Injection, ketorolac tromethamine, per 15 mg | 15 | $8 | None |
2015: 29 services
| Short return visit (20+ min) | 621 | $77,021 | $64 |
| Return visit (30+ min) | 285 | $39,352 | $93 |
| Diagnostic exam of bladder and urethra using an endoscope | 132 | $33,430 | $192 |
| Insertion of lower leg neurostimulator electrode | 14 | $15,013 | $123 |
| Ultrasound measurement of bladder capacity after voiding | 471 | $14,467 | $19 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $14,293 | None |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 32 | $10,145 | $317 |
| New patient visit (30+ min) | 105 | $9,842 | $94 |
| Complete ultrasound scan behind abdominal cavity | 65 | $8,436 | $69 |
| New patient visit (45+ min) | 47 | $6,877 | $146 |
| Electronic assessment of bladder emptying | 301 | $5,927 | $13 |
| Complete ultrasound scan of pelvis | 62 | $4,524 | $39 |
| Injection of drug or substance under skin or into muscle | 62 | $3,772 | $22 |
| Insertion of device into abdomen with pressure and urine flow rate study | 32 | $3,596 | $112 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 35 | $3,444 | $98 |
| Biopsy of prostate gland | 18 | $3,371 | $187 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,900 | $121 |
| Simple insertion of temporary bladder tube | 18 | $2,832 | $69 |
| Ultrasound scan of pelvic region through rectum | 28 | $2,641 | $94 |
| Short return visit (20+ min) | 28 | $2,198 | $40 |
| Diagnostic exam of bladder and urethra using an endoscope | 13 | $1,666 | $98 |
| Urinalysis, manual test | 289 | $1,542 | $3 |
| New patient visit (30+ min) | 19 | $1,118 | $59 |
| Ultrasonic guidance for needle placement | 17 | $988 | $58 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 27 | $850 | $19 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $791 | $33 |
| Short return visit | 15 | $587 | $35 |
| Imaging of urinary tract following injection of a contrast agent | 16 | $288 | $16 |
| Injection, garamycin, gentamicin, up to 80 mg | 169 | $277 | None |
2014: 29 services
| Return visit (30+ min) | 513 | $84,366 | $94 |
| Short return visit (20+ min) | 442 | $44,836 | $63 |
| Diagnostic exam of bladder and urethra using an endoscope | 131 | $32,547 | $188 |
| Ultrasound measurement of bladder capacity after voiding | 473 | $15,492 | $19 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $13,377 | None |
| Complete ultrasound scan behind abdominal cavity | 72 | $9,821 | $63 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 16 | $9,739 | $609 |
| Complete laser fragmentation of prostate including control of bleeding using an endoscope | 13 | $9,632 | $741 |
| New patient visit (30+ min) | 97 | $9,209 | $95 |
| New patient visit (45+ min) | 60 | $8,693 | $145 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 23 | $7,319 | $305 |
| Complete ultrasound scan of pelvis | 53 | $5,265 | $48 |
| Electronic assessment of bladder emptying | 270 | $5,077 | $13 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 30 | $4,061 | $116 |
| Injection of drug or substance under skin or into muscle | 46 | $4,040 | $22 |
| Insertion of device into abdomen with pressure and urine flow rate study | 23 | $2,666 | $111 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,327 | $111 |
| Urinalysis, manual test | 279 | $1,735 | $3 |
| Short return visit (20+ min) | 20 | $1,594 | $46 |
| Emergency department visit with moderate level of medical decision making | 12 | $1,506 | $100 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 48 | $1,486 | $19 |
| Diagnostic exam of bladder and urethra using an endoscope | 13 | $1,481 | $106 |
| Insertion of stent in ureter using an endoscope | 13 | $1,383 | $92 |
| Ultrasound scan of pelvic region through rectum | 11 | $1,028 | $93 |
| New patient visit (30+ min) | 15 | $946 | $63 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $739 | $31 |
| Short return visit | 11 | $544 | $42 |
| Imaging of urinary tract following injection of a contrast agent | 19 | $373 | $16 |
| Injection, garamycin, gentamicin, up to 80 mg | 168 | $240 | None |
2013: 39 services
| Return visit (30+ min) | 500 | $87,930 | $93 |
| Short return visit (20+ min) | 448 | $46,275 | $64 |
| Diagnostic exam of bladder and urethra using an endoscope | 132 | $31,701 | $180 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 22 | $13,976 | $608 |
| Ultrasound measurement of bladder capacity after voiding | 396 | $12,740 | $19 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $10,741 | None |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 31 | $9,930 | $320 |
| Insertion of sacral nerve neurostimulator electrode array | 18 | $9,645 | $284 |
| Complete ultrasound scan behind abdominal cavity | 72 | $9,476 | $63 |
| New patient visit (45+ min) | 68 | $9,056 | $133 |
| New patient visit (30+ min) | 94 | $8,624 | $92 |
| Insertion of sacral nerve neurostimulator electrode | 13 | $7,654 | $547 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 50 | $7,121 | $125 |
| Crushing of stone of ureter using an endoscope | 13 | $5,569 | $348 |
| Injection of drug or substance under skin or into muscle | 33 | $5,348 | $24 |
| Limited ultrasound scan of pelvis | 61 | $5,176 | $75 |
| Study of rectum sensitivity and function | 11 | $4,783 | $217 |
| Insertion of device into abdomen with pressure and urine flow rate study | 39 | $4,438 | $114 |
| Electronic assessment of bladder emptying | 225 | $3,888 | $12 |
| Ultrasonic guidance for needle placement | 15 | $3,246 | $216 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 12 | $3,216 | $230 |
| Dilation of urethra using an endoscope | 11 | $3,127 | $261 |
| Biopsy of prostate gland | 15 | $2,972 | $198 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,166 | $114 |
| Insertion of stent in ureter using an endoscope | 23 | $1,979 | $73 |
| Limited ultrasound scan of abdomen | 18 | $1,931 | $107 |
| Emergency department visit with moderate level of medical decision making | 17 | $1,817 | $96 |
| Urinalysis, manual test | 276 | $1,767 | $3 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 42 | $1,451 | $19 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 14 | $1,435 | $68 |
| Ultrasound scan of pelvic region through rectum | 17 | $1,228 | $72 |
| Simple bladder irrigation and/or instillation | 11 | $957 | $80 |
| Long return visit (40+ min) | 11 | $939 | $85 |
| Short return visit | 18 | $678 | $36 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $613 | $31 |
| Imaging of urinary tract following injection of a contrast agent | 15 | $326 | $16 |
| Injection, garamycin, gentamicin, up to 80 mg | 182 | $250 | None |
| Imaging guidance for procedure, 60 minutes or less | 12 | $91 | $8 |
| Injection, ceftriaxone sodium, per 250 mg | 11 | $44 | None |
Medicaid work
$1,949 in 2022
Medicaid paid $1,949 for 32 billed services this clinician did in 2022, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 32 | $1,949 |
| 2022 | 32 | 1 | 18 | $1,949 |
| 2021 | 44 | 2 | 15 | $2,166 |
| 2020 | 29 | 1 | 16 | $1,760 |
| 2019 | 162 | 1 | 28 | $4,628 |
| 2018 | 266 | 2 | 26 | $8,888 |
See the largest Medicaid services in earlier years
2021
| Return visit (30+ min) | 30 | $1,696 |
| Short return visit (20+ min) | 14 | $469 |
2020
| Return visit (30+ min) | 29 | $1,760 |
2019
| Short return visit (20+ min) | 162 | $4,628 |
2018
| Short return visit (20+ min) | 254 | $8,053 |
| New patient visit (30+ min) | 12 | $835 |
Drugs they prescribed that Part D paid
$176,889
Pharmacies billed $176,889 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (22 of 1,398) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
1,210 generic and fewer than 11 brand-name prescriptions · $176,889 in drug cost · 164 antibiotic prescriptions to 88 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 131 | $99,533 | $760 |
| Gemtesa | 47 | $33,593 | $715 |
| Methenamine Hippurate | 60 | $7,432 | $124 |
| Tamsulosin | 280 | $5,597 | $20 |
| Silodosin | 55 | $5,520 | $100 |
See all 22 drugs
| Myrbetriq | 131 | $99,533 | $760 |
| Gemtesa | 47 | $33,593 | $715 |
| Methenamine Hippurate | 60 | $7,432 | $124 |
| Tamsulosin | 280 | $5,597 | $20 |
| Silodosin | 55 | $5,520 | $100 |
| Alfuzosin Hcl Er | 149 | $3,289 | $22 |
| Testosterone Cypionate | 84 | $3,085 | $37 |
| Estradiol | 34 | $2,892 | $85 |
| Desmopressin Acetate | 25 | $2,119 | $85 |
| Dutasteride | 63 | $1,371 | $22 |
| Finasteride | 64 | $1,116 | $17 |
| Tadalafil | 21 | $721 | $34 |
| Cephalexin | 61 | $382 | $6 |
| Nitrofurantoin Mono-Macro | 23 | $368 | $16 |
| Amitriptyline | 32 | $222 | $7 |
| Doxycycline Hyclate | 22 | $179 | $8 |
| Sildenafil Citrate | 20 | $104 | $5 |
| Oxycodone-Acetaminophen | 16 | $95 | $6 |
| Ciprofloxacin | 16 | $93 | $6 |
| Anastrozole | 13 | $91 | $7 |
| Sulfamethoxazole-Trimethoprim | 28 | $64 | $2 |
| Alprazolam | 13 | $37 | $3 |
Year by year
| 2024 | 1,398 | 320 | 2% (22) | None | $176,889 |
| 2023 | 1,283 | 290 | 1% (18) | None | $164,254 |
| 2022 | 1,228 | 288 | 1% (13) | None | $148,876 |
| 2021 | 1,393 | 337 | 2% (27) | None | $157,488 |
| 2020 | 1,566 | 357 | 1% (19) | None | $218,323 |
| 2019 | 1,802 | 431 | 2% (33) | None | $221,120 |
| 2018 | 1,716 | 424 | 3% (44) | None | $253,252 |
| 2017 | 1,683 | 429 | 4% (66) | None | $252,136 |
| 2016 | 1,635 | 382 | 4% (57) | None | $240,752 |
| 2015 | 1,558 | 381 | 4% (57) | None | $204,719 |
| 2014 | 1,520 | 381 | 4% (54) | None | $155,765 |
| 2013 | 1,488 | 352 | 3% (40) | None | $141,530 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Myrbetriq | 119 | $94,246 | $792 |
| Gemtesa | 28 | $16,278 | $581 |
| Methenamine Hippurate | 81 | $10,053 | $124 |
| Silodosin | 45 | $7,502 | $167 |
| Tamsulosin | 254 | $6,196 | $24 |
| Alfuzosin Hcl Er | 159 | $5,948 | $37 |
| Dutasteride | 61 | $4,206 | $69 |
| Estradiol | 22 | $3,405 | $155 |
| Testosterone Cypionate | 73 | $2,233 | $31 |
| Desmopressin Acetate | 20 | $1,231 | $62 |
| Finasteride | 52 | $1,049 | $20 |
| Tadalafil | 26 | $804 | $31 |
| Nitrofurantoin Mono-Macro | 27 | $758 | $28 |
| Cephalexin | 54 | $363 | $7 |
| Doxycycline Hyclate | 17 | $247 | $15 |
| Anastrozole | 14 | $228 | $16 |
| Amitriptyline | 24 | $212 | $9 |
| Sulfamethoxazole-Trimethoprim | 42 | $195 | $5 |
| Ciprofloxacin | 23 | $144 | $6 |
| Oxycodone-Acetaminophen | 16 | $49 | $3 |
2022: 21 drugs
| Myrbetriq | 134 | $97,188 | $725 |
| Methenamine Hippurate | 87 | $8,094 | $93 |
| Tamsulosin | 270 | $6,523 | $24 |
| Silodosin | 33 | $6,059 | $184 |
| Alfuzosin Hcl Er | 143 | $5,471 | $38 |
| Dutasteride | 36 | $3,509 | $97 |
| Estradiol | 20 | $2,367 | $118 |
| Desmopressin Acetate | 25 | $2,058 | $82 |
| Testosterone Cypionate | 53 | $1,888 | $36 |
| Finasteride | 82 | $1,410 | $17 |
| Tadalafil | 16 | $694 | $43 |
| Doxazosin Mesylate | 11 | $436 | $40 |
| Amitriptyline | 43 | $430 | $10 |
| Doxycycline Hyclate | 16 | $332 | $21 |
| Cephalexin | 53 | $300 | $6 |
| Nitrofurantoin Mono-Macro | 18 | $266 | $15 |
| Econazole Nitrate | 11 | $253 | $23 |
| Ciprofloxacin | 31 | $217 | $7 |
| Sulfamethoxazole-Trimethoprim | 26 | $81 | $3 |
| Oxycodone-Acetaminophen | 12 | $56 | $5 |
| Fluconazole | 14 | $56 | $4 |
2021: 22 drugs
| Myrbetriq | 143 | $95,074 | $665 |
| Tamsulosin | 322 | $6,889 | $21 |
| Silodosin | 39 | $5,368 | $138 |
| Alfuzosin Hcl Er | 160 | $4,935 | $31 |
| Methenamine Hippurate | 36 | $4,104 | $114 |
| Estradiol | 33 | $4,000 | $121 |
| Dutasteride | 32 | $3,093 | $97 |
| Tolterodine Tartrate Er | 19 | $2,996 | $158 |
| Testosterone Cypionate | 53 | $2,646 | $50 |
| Desmopressin Acetate | 26 | $1,704 | $66 |
| Finasteride | 80 | $1,639 | $20 |
| Nitrofurantoin Mono-Macro | 40 | $1,073 | $27 |
| Doxycycline Hyclate | 26 | $862 | $33 |
| Tadalafil | 16 | $761 | $48 |
| Amitriptyline | 53 | $527 | $10 |
| Cephalexin | 83 | $517 | $6 |
| Doxazosin Mesylate | 11 | $468 | $43 |
| Terazosin | 15 | $423 | $28 |
| Oxybutynin Chloride Er | 16 | $373 | $23 |
| Oxycodone-Acetaminophen | 24 | $138 | $6 |
| Sulfamethoxazole-Trimethoprim | 47 | $129 | $3 |
| Ciprofloxacin | 15 | $93 | $6 |
2020: 21 drugs
| Myrbetriq | 245 | $148,084 | $604 |
| Tamsulosin | 343 | $6,439 | $19 |
| Methenamine Hippurate | 42 | $6,084 | $145 |
| Silodosin | 36 | $5,913 | $164 |
| Alfuzosin Hcl Er | 170 | $5,511 | $32 |
| Tolterodine Tartrate Er | 39 | $4,485 | $115 |
| Estradiol | 33 | $4,403 | $133 |
| Testosterone | 22 | $4,071 | $185 |
| Testosterone Cypionate | 65 | $3,858 | $59 |
| Dutasteride | 29 | $2,956 | $102 |
| Finasteride | 87 | $2,082 | $24 |
| Tadalafil | 17 | $1,427 | $84 |
| Desmopressin Acetate | 30 | $1,406 | $47 |
| Nitrofurantoin | 16 | $617 | $39 |
| Nitrofurantoin Mono-Macro | 36 | $487 | $14 |
| Amitriptyline | 43 | $399 | $9 |
| Doxycycline Hyclate | 20 | $351 | $18 |
| Cephalexin | 43 | $266 | $6 |
| Ciprofloxacin | 37 | $209 | $6 |
| Sulfamethoxazole-Trimethoprim | 60 | $182 | $3 |
| Oxycodone-Acetaminophen | 13 | $66 | $5 |
2019: 29 drugs
| Myrbetriq | 234 | $116,852 | $499 |
| Estradiol | 49 | $9,468 | $193 |
| Tadalafil | 30 | $8,952 | $298 |
| Silodosin | 41 | $8,210 | $200 |
| Rapaflo | 15 | $7,519 | $501 |
| Tamsulosin | 310 | $6,087 | $20 |
| Estrace | 14 | $5,134 | $367 |
| Methenamine Hippurate | 31 | $3,852 | $124 |
| Alfuzosin Hcl Er | 171 | $3,779 | $22 |
| Dutasteride | 35 | $3,491 | $100 |
| Testosterone | 12 | $3,175 | $265 |
| Tolterodine Tartrate Er | 33 | $3,106 | $94 |
| Testosterone Cypionate | 49 | $2,937 | $60 |
| Finasteride | 64 | $2,118 | $33 |
| Nitrofurantoin Mono-Macro | 78 | $1,538 | $20 |
| Nitrofurantoin | 21 | $1,092 | $52 |
| Desmopressin Acetate | 19 | $1,061 | $56 |
| Sulfamethoxazole-Trimethoprim | 150 | $696 | $5 |
| Oxybutynin Chloride | 19 | $523 | $28 |
| Doxazosin Mesylate | 12 | $502 | $42 |
| Amitriptyline | 68 | $491 | $7 |
| Cephalexin | 59 | $450 | $8 |
| Ciprofloxacin | 44 | $358 | $8 |
| Terazosin | 11 | $320 | $29 |
| Doxycycline Monohydrate | 18 | $281 | $16 |
| Trimethoprim | 13 | $233 | $18 |
| Fluconazole | 23 | $165 | $7 |
| Oxycodone-Acetaminophen | 31 | $136 | $4 |
| Diazepam | 11 | $14 | $1 |
2018: 31 drugs
| Myrbetriq | 219 | $101,422 | $463 |
| Rapaflo | 79 | $37,355 | $473 |
| Cialis | 30 | $19,814 | $660 |
| Vesicare | 23 | $10,472 | $455 |
| Androgel | 13 | $9,335 | $718 |
| Tamsulosin | 315 | $7,314 | $23 |
| Premarin | 16 | $5,422 | $339 |
| Estrace | 16 | $5,089 | $318 |
| Estradiol | 21 | $4,476 | $213 |
| Tolterodine Tartrate Er | 24 | $3,202 | $133 |
| Methenamine Hippurate | 21 | $2,820 | $134 |
| Nitrofurantoin Mono-Macro | 76 | $2,591 | $34 |
| Testosterone Cypionate | 53 | $2,133 | $40 |
| Finasteride | 76 | $2,071 | $27 |
| Dutasteride-Tamsulosin | 14 | $1,985 | $142 |
| Dutasteride | 29 | $1,887 | $65 |
| Potassium Citrate Er | 14 | $1,681 | $120 |
| Alfuzosin Hcl Er | 77 | $1,675 | $22 |
| Trospium Chloride | 18 | $1,512 | $84 |
| Desmopressin Acetate | 24 | $1,415 | $59 |
| Nitrofurantoin | 19 | $1,081 | $57 |
| Oxybutynin Chloride | 36 | $888 | $25 |
| Cephalexin | 68 | $824 | $12 |
| Sulfamethoxazole-Trimethoprim | 124 | $701 | $6 |
| Trimethoprim | 25 | $513 | $21 |
| Amitriptyline | 54 | $478 | $9 |
| Terazosin | 21 | $270 | $13 |
| Oxycodone-Acetaminophen | 31 | $218 | $7 |
| Ciprofloxacin | 29 | $183 | $6 |
| Doxycycline Monohydrate | 15 | $178 | $12 |
| Fluconazole | 11 | $51 | $5 |
2017: 30 drugs
| Myrbetriq | 183 | $81,283 | $444 |
| Rapaflo | 139 | $57,284 | $412 |
| Cialis | 42 | $21,989 | $524 |
| Vesicare | 31 | $13,891 | $448 |
| Estrace | 28 | $9,261 | $331 |
| Tamsulosin | 252 | $6,707 | $27 |
| Androgel | 11 | $6,309 | $574 |
| Gelnique | 12 | $6,269 | $522 |
| Tolterodine Tartrate Er | 14 | $3,445 | $246 |
| Methenamine Hippurate | 17 | $2,912 | $171 |
| Testosterone Cypionate | 62 | $2,409 | $39 |
| Potassium Citrate Er | 16 | $2,305 | $144 |
| Finasteride | 88 | $2,282 | $26 |
| Dutasteride | 17 | $2,151 | $127 |
| Desmopressin Acetate | 11 | $2,077 | $189 |
| Nitrofurantoin Mono-Macro | 61 | $2,053 | $34 |
| Dutasteride-Tamsulosin | 12 | $1,873 | $156 |
| Oxybutynin Chloride Er | 21 | $1,023 | $49 |
| Oxybutynin Chloride | 30 | $845 | $28 |
| Cephalexin | 78 | $743 | $10 |
| Alfuzosin Hcl Er | 42 | $738 | $18 |
| Sulfamethoxazole-Trimethoprim | 146 | $610 | $4 |
| Trimethoprim | 27 | $535 | $20 |
| Terazosin | 14 | $369 | $26 |
| Oxycodone-Acetaminophen | 56 | $335 | $6 |
| Ciprofloxacin | 46 | $321 | $7 |
| Doxycycline Monohydrate | 22 | $319 | $15 |
| Amitriptyline | 28 | $278 | $10 |
| Fluconazole | 11 | $31 | $3 |
| Diazepam | 15 | $14 | $1 |
2016: 33 drugs
| Myrbetriq | 157 | $64,056 | $408 |
| Rapaflo | 160 | $57,315 | $358 |
| Cialis | 43 | $17,327 | $403 |
| Vesicare | 18 | $8,452 | $470 |
| Gelnique | 11 | $7,581 | $689 |
| Tamsulosin | 247 | $7,494 | $30 |
| Enablex | 15 | $6,707 | $447 |
| Dutasteride-Tamsulosin | 22 | $4,816 | $219 |
| Estrace | 13 | $3,845 | $296 |
| Potassium Citrate Er | 31 | $3,774 | $122 |
| Trospium Chloride Er | 15 | $3,680 | $245 |
| Vagifem | 11 | $3,197 | $291 |
| Finasteride | 140 | $2,755 | $20 |
| Dutasteride | 17 | $2,563 | $151 |
| Trospium Chloride | 17 | $2,397 | $141 |
| Lidocaine | 11 | $1,671 | $152 |
| Nitrofurantoin Mono-Macro | 49 | $1,430 | $29 |
| Econazole Nitrate | 21 | $1,377 | $66 |
| Testosterone Cypionate | 31 | $1,315 | $42 |
| Methenamine Hippurate | 11 | $1,025 | $93 |
| Cephalexin | 71 | $1,000 | $14 |
| Nitrofurantoin | 23 | $868 | $38 |
| Desmopressin Acetate | 15 | $741 | $49 |
| Alfuzosin Hcl Er | 39 | $727 | $19 |
| Sulfamethoxazole-Trimethoprim | 117 | $633 | $5 |
| Oxybutynin Chloride | 23 | $585 | $25 |
| Oxycodone-Acetaminophen | 43 | $563 | $13 |
| Trimethoprim | 28 | $444 | $16 |
| Ciprofloxacin | 34 | $321 | $9 |
| Terazosin | 17 | $246 | $14 |
| Amitriptyline | 16 | $145 | $9 |
| Fluconazole | 12 | $83 | $7 |
| Allopurinol | 12 | $48 | $4 |
2015: 33 drugs
| Myrbetriq | 111 | $45,263 | $408 |
| Rapaflo | 118 | $38,592 | $327 |
| Avodart | 46 | $13,279 | $289 |
| Cialis | 25 | $8,239 | $330 |
| Tamsulosin | 201 | $8,044 | $40 |
| Enablex | 20 | $7,466 | $373 |
| Jalyn | 19 | $5,591 | $294 |
| Estrace | 23 | $5,178 | $225 |
| Vagifem | 16 | $5,059 | $316 |
| Premarin | 17 | $4,893 | $288 |
| Potassium Citrate Er | 43 | $4,788 | $111 |
| Gelnique | 13 | $3,779 | $291 |
| Trospium Chloride | 18 | $2,952 | $164 |
| Finasteride | 156 | $2,352 | $15 |
| Nitrofurantoin Mono-Macro | 42 | $1,549 | $37 |
| Testosterone Cypionate | 21 | $1,497 | $71 |
| Nitrofurantoin | 21 | $1,226 | $58 |
| Cephalexin | 116 | $1,039 | $9 |
| Alfuzosin Hcl Er | 37 | $800 | $22 |
| Oxybutynin Chloride Er | 14 | $751 | $54 |
| Bethanechol Chloride | 12 | $581 | $48 |
| Trimethoprim | 35 | $518 | $15 |
| Oxybutynin Chloride | 17 | $472 | $28 |
| Sulfamethoxazole-Trimethoprim | 100 | $419 | $4 |
| Oxycodone-Acetaminophen | 25 | $404 | $16 |
| Ciprofloxacin | 36 | $247 | $7 |
| Hydrocodone-Acetaminophen | 15 | $206 | $14 |
| Acetaminophen-Codeine | 12 | $131 | $11 |
| Fluconazole | 17 | $124 | $7 |
| Terazosin | 15 | $122 | $8 |
| Allopurinol | 14 | $94 | $7 |
| Amitriptyline | 11 | $87 | $8 |
| Levofloxacin | 11 | $70 | $6 |
2014: 30 drugs
| Rapaflo | 92 | $25,173 | $274 |
| Myrbetriq | 42 | $16,791 | $400 |
| Avodart | 78 | $16,039 | $206 |
| Enablex | 42 | $13,917 | $331 |
| Vesicare | 25 | $6,738 | $270 |
| Premarin | 27 | $5,608 | $208 |
| Estrace | 24 | $5,384 | $224 |
| Tamsulosin | 196 | $4,799 | $24 |
| Gelnique | 20 | $4,757 | $238 |
| Trospium Chloride Er | 19 | $4,223 | $222 |
| Vagifem | 15 | $3,831 | $255 |
| Gelnique | 12 | $2,635 | $220 |
| Finasteride | 108 | $2,248 | $21 |
| Testosterone Cypionate | 31 | $2,178 | $70 |
| Nitrofurantoin Mono-Macro | 66 | $2,142 | $32 |
| Cephalexin | 153 | $1,239 | $8 |
| Alfuzosin Hcl Er | 48 | $1,212 | $25 |
| Oxybutynin Chloride | 34 | $935 | $28 |
| Econazole Nitrate | 17 | $840 | $49 |
| Nitrofurantoin | 20 | $738 | $37 |
| Doxycycline Monohydrate | 11 | $652 | $59 |
| Desmopressin Acetate | 11 | $652 | $59 |
| Trimethoprim | 37 | $551 | $15 |
| Hydrocodone-Acetaminophen | 29 | $434 | $15 |
| Sulfamethoxazole-Trimethoprim | 69 | $423 | $6 |
| Ciprofloxacin | 44 | $269 | $6 |
| Oxycodone-Acetaminophen | 11 | $159 | $14 |
| Fluconazole | 25 | $157 | $6 |
| Levofloxacin | 18 | $117 | $6 |
| Amitriptyline | 13 | $52 | $4 |
2013: 28 drugs
| Rapaflo | 87 | $20,667 | $238 |
| Enablex | 41 | $13,517 | $330 |
| Avodart | 59 | $11,525 | $195 |
| Oxytrol | 21 | $11,465 | $546 |
| Vesicare | 40 | $10,445 | $261 |
| Premarin | 34 | $6,407 | $188 |
| Tamsulosin | 239 | $5,787 | $24 |
| Gelnique | 22 | $4,544 | $207 |
| Detrol La | 18 | $4,199 | $233 |
| Vagifem | 26 | $4,149 | $160 |
| Finasteride | 110 | $3,724 | $34 |
| Toviaz | 14 | $3,258 | $233 |
| Testosterone Cypionate | 35 | $2,858 | $82 |
| Gelnique | 13 | $2,467 | $190 |
| Nitrofurantoin | 15 | $1,545 | $103 |
| Nitrofurantoin Mono-Macro | 34 | $1,329 | $39 |
| Cephalexin | 151 | $1,141 | $8 |
| Alfuzosin | 31 | $955 | $31 |
| Fluconazole | 52 | $932 | $18 |
| Trimethoprim | 41 | $890 | $22 |
| Lidocaine | 12 | $806 | $67 |
| Sulfamethoxazole-Trimethoprim | 63 | $451 | $7 |
| Ciprofloxacin | 56 | $331 | $6 |
| Doxazosin Mesylate | 18 | $261 | $15 |
| Oxybutynin Chloride | 12 | $245 | $20 |
| Terazosin | 13 | $195 | $15 |
| Hydrocodone-Acetaminophen | 21 | $168 | $8 |
| Oxycodone-Acetaminophen | 12 | $104 | $9 |
Money from drug and device companies
$457 in 2025
| 2025 | 5 | 15 | None | $457 |
| 2024 | 5 | 20 | None | $13,673 |
| 2023 | 6 | 22 | None | $486 |
| 2022 | 16 | 34 | $2,575 | $3,283 |
| 2021 | 21 | 34 | $400 | $1,043 |
| 2020 | 16 | 28 | $2,000 | $2,479 |
| 2019 | 11 | 16 | None | $571 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Gemtesa | $290 | 11 payments
|
| Teleflex | Barrigel | $73 | 1 payment
|
| Telix Pharmaceuticals | Illuccix | $34 | 1 payment
|
| Urogen Pharma | Jelmyto | $30 | 1 payment
|
| Abbvie | Botox | $29 | 1 payment
|
See all 15 published payments
| Sumitomo Pharma America | Meals · 2025-12-30 | Gemtesa | $28 |
| Urogen Pharma | Meals · 2025-11-20 | Jelmyto | $30 |
| Sumitomo Pharma America | Meals · 2025-11-13 | Gemtesa | $18 |
| Sumitomo Pharma America | Meals · 2025-11-11 | Gemtesa | $42 |
| Sumitomo Pharma America | Meals · 2025-09-17 | Gemtesa | $17 |
| Sumitomo Pharma America | Meals · 2025-08-05 | Gemtesa | $35 |
| Teleflex | Meals · 2025-07-18 | Barrigel | $73 |
| Sumitomo Pharma America | Meals · 2025-07-16 | Gemtesa | $25 |
| Sumitomo Pharma America | Meals · 2025-06-03 | Gemtesa | $35 |
| Abbvie | Meals · 2025-05-01 | Botox | $29 |
| Sumitomo Pharma America | Meals · 2025-04-25 | Gemtesa | $16 |
| Sumitomo Pharma America | Meals · 2025-02-21 | Gemtesa | $33 |
| Sumitomo Pharma America | Meals · 2025-02-07 | Gemtesa | $17 |
| Sumitomo Pharma America | Meals · 2025-02-05 | Gemtesa | $25 |
| Telix Pharmaceuticals | Meals · 2025-01-30 | Illuccix | $34 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $13,673
| Olympus America | Soltive | $13,176 | 1 payment
|
| Sumitomo Pharma America | Gemtesa | $347 | 12 payments
|
| Endo USA | Xiaflex | $100 | 4 payments
|
| Coloplast | Altis | $36 | 2 payments
|
| Axonics | Axonics | $14 | 1 payment
|
2023: $486
| Sumitomo Pharma America | Gemtesa | $292 | 14 payments
|
| Endo Pharmaceuticals | Xiaflex | $73 | 3 payments
|
| Hologic Sales and Service | Aptima | $37 | 2 payments
|
| Coloplast | Altis | $36 | 1 payment
|
| Astellas Pharma US | Veozah | $33 | 1 payment
|
| Cranial Technologies | Doc Band | $16 | 1 payment
|
2022: $3,283
| Valencia Technologies | Ecoin Device Kit | $2,575 | 1 payment
|
| Urovant Sciences | Gemtesa | $309 | 13 payments
|
| Hologic | Thinprep 2000 Processor | $48 | 2 payments
|
| Bausch Health US | Aplenzin | $48 | 2 payments
|
| Endo Pharmaceuticals | Aveed | $43 | 2 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $39 | 2 payments
|
| Evofem Biosciences | Phexxi | $38 | 2 payments
|
| Mayne Pharma | None | $35 | 2 payments
|
| kaleo | Auvi-Q | $26 | 1 payment
|
| Becton Dickinson and | Bd Onclarity | $23 | 1 payment
|
| Avion Pharmaceuticals | Divigel | $20 | 1 payment
|
| Abbvie | Qulipta | $18 | 1 payment
|
| Aspira Women's Health | Ova1 | $17 | 1 payment
|
| Allergan | Botox | $15 | 1 payment
|
| Olympus America | Itind System | $14 | 1 payment
|
| Merck Sharp & Dohme | Gardasil 9 | $14 | 1 payment
|
2021: $1,043
| Teleflex | Urolift System | $436 | 3 payments
|
| Endo Pharmaceuticals | Xiaflex | $102 | 5 payments
|
| Urovant Sciences | Gemtesa | $93 | 5 payments
|
| kaleo | Auvi-Q | $68 | 3 payments
|
| Pfizer | Prevnar 13 | $41 | 2 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $26 | 1 payment
|
| Boston Scientific | Lithovue Empower | $25 | 1 payment
|
| AbbVie | Ubrelvy | $25 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $23 | 1 payment
|
| Photocure | Cysview | $21 | 1 payment
|
| Evofem Biosciences | Phexxi | $20 | 1 payment
|
| Allergan | Botox | $19 | 1 payment
|
| TherapeuticsMD | Annovera | $19 | 1 payment
|
| Mayne Pharma | None | $18 | 1 payment
|
| Exeltis USA | Slynd | $18 | 1 payment
|
| Roche Diagnostics | Cintec Plus Cytology | $18 | 1 payment
|
| Coloplast | Altis | $16 | 1 payment
|
| Axonics | Axonics R-Snm System | $16 | 1 payment
|
| Sage Therapeutics | Zulresso | $15 | 1 payment
|
| Janssen Biotech | Erleada | $13 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $11 | 1 payment
|
2020: $2,479
| Arthrex | None | $2,000 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $125 | 10 payments
|
| Allergan | Botox | $49 | 2 payments
|
| Roche Diagnostics | Rs Harmony Test Related Products | $45 | 2 payments
|
| Pfizer | Toviaz | $39 | 1 payment
|
| kaleo | Auvi-Q | $39 | 2 payments
|
| Bausch Health US | Aplenzin | $28 | 1 payment
|
| AbbVie | Lo Loestrin Fe | $22 | 1 payment
|
| Rochester Medical | None | $20 | 1 payment
|
| Urogen Pharma | Jelmyto | $19 | 1 payment
|
| TherapeuticsMD | Imvexxy | $18 | 1 payment
|
| NeoTract | Urolift | $17 | 1 payment
|
| Coloplast | Penile & Testicular Reconstructn | $17 | 1 payment
|
| Agiliti Surgical | None | $16 | 1 payment
|
| Cranial Technologies | Doc Band | $12 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $11 | 1 payment
|
2019: $571
| Boston Scientific | Ams | $196 | 3 payments
|
| Arthrex | None | $104 | 1 payment
|
| Janssen Biotech | Erleada | $53 | 2 payments
|
| NeoTract | Urolift | $47 | 2 payments
|
| Allergan | Botox | $38 | 2 payments
|
| Ferring Pharmaceuticals | Nocdurna | $36 | 1 payment
|
| AbbVie | Lupron Depot | $23 | 1 payment
|
| Roche Diagnostics | Rs Harmony Test Related Products | $22 | 1 payment
|
| Hologic | Aptima Hpv | $21 | 1 payment
|
| C. R. Bard Inc. & Subsidiaries | None | $19 | 1 payment
|
| Antares Pharma | Otrexup | $11 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 8.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1568466589
- Licence
- CA A79072California A79072: Current · expires 2027-07-31
- Trained
- University of California, Irvine, California College of Medicine, 1996
- Group
- UCSF Health Medical Foundation · El Camino Health Medical Network LLC
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 570 El Camino Real # 150-446, Redwood City, CA, 94063
- NPI first listed
- 2005-06-08
- NPI last updated
- 2023-09-14
- NPI record certified
- 2023-09-14
This is when the NPI record was last certified, not a medical board exam.